82 related articles for article (PubMed ID: 31567867)
1. A critical appraisal of vasomotor symptom assessment tools used in clinical trials evaluating hormone therapy compared to placebo.
Christakis MK; Strobino DM; Shen W
Menopause; 2019 Nov; 26(11):1334-1341. PubMed ID: 31567867
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of fezolinetant in alleviating vasomotor symptoms linked to Menopause.: A systematic review and Meta-Analysis.
Elnaga AAA; Alsaied MA; Elettreby AM; Ramadan A
Eur J Obstet Gynecol Reprod Biol; 2024 Jun; 297():142-152. PubMed ID: 38640780
[TBL] [Abstract][Full Text] [Related]
3. Fezolinetant impact on health-related quality of life for vasomotor symptoms due to the menopause: Pooled data from SKYLIGHT 1 and SKYLIGHT 2 randomised controlled trials.
Cano A; Nappi RE; Santoro N; Stute P; Blogg M; English ML; Morga A; Scrine L; Siddiqui E; Ottery FD
BJOG; 2024 Aug; 131(9):1296-1305. PubMed ID: 38320967
[TBL] [Abstract][Full Text] [Related]
4. Management of the Vasomotor Symptoms of Menopause: Twofers in Your Clinical Toolbox.
Kling JM; Stuenkel CA; Faubion SS
Mayo Clin Proc; 2024 Jul; 99(7):1142-1148. PubMed ID: 38960498
[TBL] [Abstract][Full Text] [Related]
5. Design of OASIS 1 and 2: phase 3 clinical trials assessing the efficacy and safety of elinzanetant for the treatment of vasomotor symptoms associated with menopause.
Pinkerton JV; Simon J; Panay N; Seitz C; Parke S; Caetano C; Mellinger U; Haseli Mashhadi N; Haberland C; Atanackovic G; Holz C; Mao G; Morrison M; Nisius S; Schaefers M; Zuurman L
Menopause; 2024 Jun; 31(6):522-529. PubMed ID: 38564691
[TBL] [Abstract][Full Text] [Related]
6. Fezolinetant for the treatment of vasomotor symptoms associated with menopause: a meta-analysis.
Chavez MP; Pasqualotto E; Ferreira ROM; Hohl A; de Moraes FCA; Schmidt PHS; Rodrigues ALSO; de Sa JR
Climacteric; 2024 Jun; 27(3):245-254. PubMed ID: 38619017
[TBL] [Abstract][Full Text] [Related]
7. Treating moderate-to-severe menopausal vasomotor symptoms with fezolinetant: analysis of responders using pooled data from two phase 3 studies (SKYLIGHT 1 and 2).
Nappi RE; Johnson KA; Stute P; Blogg M; English M; Morga A; Scrine L; Siddiqui E; Ottery FD
Menopause; 2024 Jun; 31(6):512-521. PubMed ID: 38626380
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of fezolinetant, a neurokinin-3 antagonist, in treating vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis.
Rahman UA; Kashif TB; Usman M; Rana M; Hasanain M; Anjum MU; Cheema HA; Jaffar H; Bhattarai P
Medicine (Baltimore); 2023 Dec; 102(50):e36592. PubMed ID: 38115258
[TBL] [Abstract][Full Text] [Related]
9. Systematic review of neurokinin-3 receptor antagonists for the management of vasomotor symptoms of menopause.
Cieri-Hutcherson NE; Marji EK; Hutcherson TC
Menopause; 2024 Apr; 31(4):342-354. PubMed ID: 38471077
[TBL] [Abstract][Full Text] [Related]
10. Predictors of vasomotor symptoms among breast cancer survivors.
Reeves KW; Pennell M; Foraker RE; Crandall CJ; Stefanick M; Paskett ED
J Cancer Surviv; 2018 Jun; 12(3):379-387. PubMed ID: 29427202
[TBL] [Abstract][Full Text] [Related]
11. Nonhormone therapies for vasomotor symptom management.
Iyer TK; Fiffick AN; Batur P
Cleve Clin J Med; 2024 Apr; 91(4):237-244. PubMed ID: 38561208
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Fezolinetant for the Treatment of Menopause-Associated Vasomotor Symptoms: A Meta-analysis.
Bonga KN; Mishra A; Maiti R; Padhy BM; Meher BR; Srinivasan A
Obstet Gynecol; 2024 Mar; 143(3):393-402. PubMed ID: 38227939
[TBL] [Abstract][Full Text] [Related]
13. Correlations among Core Outcomes in Menopause-recommended vasomotor symptom outcomes in MsFLASH trials.
Carpenter JS; Larson JC; Hunter MS; Lensen S; Chen CX; Guthrie KA
Menopause; 2024 Jan; 31(1):3-9. PubMed ID: 37963308
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials.
Akhtar SMM; Ali A; Khan MS; Khan V; Fareed A; Saleem SZ; Mumtaz M; Ahsan MN; Iqbal S; Asghar MS
Int J Gynaecol Obstet; 2024 Apr; ():. PubMed ID: 38563867
[TBL] [Abstract][Full Text] [Related]
15. Menopausal symptom management: Fezolinetant's varied doses provide effective relief for vasomotor symptoms in women - A meta-analysis of 3291 participants.
Elhusein AM; Fadlalmola HA; Abedelwahed HH; Elshaikh AA; Banaga AE; Alrahman MHF; Abdelgadim NH; Mohammed IH; Abdalla AAA; Abdalla FAM; Abd Allah EM; Abbas NI; Alhujaili AD; Almkiy EA; Idress EA; Awadalkareem EM; Abdeldafie SY; Balusamy P; Mohamed RA; Aloufi RSM; Habiballa M; Abdelmalik MA; Alhejaili MM; Ibrahim IA; Masaad HK
Afr J Reprod Health; 2024 Mar; 28(3):99-113. PubMed ID: 38583073
[TBL] [Abstract][Full Text] [Related]
16. Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial.
Veerus P; Fischer K; Hovi SL; Karro H; Rahu M; Hemminki E
BMC Womens Health; 2008 Mar; 8():5. PubMed ID: 18366766
[TBL] [Abstract][Full Text] [Related]
17. [Differential diagnosis of vasomotor symptoms. Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines].
Maitrot-Mantelet L; Perol S; Plu-Bureau G
Gynecol Obstet Fertil Senol; 2021 May; 49(5):329-334. PubMed ID: 33840610
[TBL] [Abstract][Full Text] [Related]
18. Validity, cut-points, and minimally important differences for two hot flash-related daily interference scales.
Carpenter JS; Bakoyannis G; Otte JL; Chen CX; Rand KL; Woods N; Newton K; Joffe H; Manson JE; Freeman EW; Guthrie KA
Menopause; 2017 Aug; 24(8):877-885. PubMed ID: 28509814
[TBL] [Abstract][Full Text] [Related]
19. Recommended measurement instruments for menopausal vasomotor symptoms: the COMMA (Core Outcomes in Menopause) consortium.
Lensen S; Paramanandam VS; Gabes M; Kann G; Donhauser T; Waters NF; Li AD; Peate M; Susanto NS; Caughey LE; Rangoonwal F; Liu J; Condron P; Anagnostis P; Archer DF; Avis NE; Bell RJ; Carpenter JS; Chedraui P; Christmas M; Davies M; Hillard T; Hunter MS; Iliodromiti S; Jaff NG; Jaisamrarn U; Joffe H; Khandelwal S; Kiesel L; Maki PM; Mishra GD; Nappi RE; Panay N; Pines A; Roberts H; Rozenberg S; Rueda C; Shifren J; Simon JA; Simpson P; Siregar MFG; Stute P; Garcia JT; Vincent AJ; Wolfman W; Hickey M
Menopause; 2024 Jul; 31(7):582-590. PubMed ID: 38688464
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
